Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
A composition and method for promoting neutrophil survival and activation such as the treatment of neutropenia arising as an undesirable side effect of chemotherapy and radiation therapy. A composition containing medium-chain fatty acids, such as Capri acid or caprylic acid, or salts or triglycerides thereof, or mono- or diglycerides or other analogues thereof or medium-chain triglycerides (MCT) is administered to a human or animal needing treatment in an amount sufficient to reduce or eliminate neutropenia. The composition is administered in an amount effective to treat the disorder. The methods are also useful in the management of bone narrow transplantation and in the treatment of various neutropenic diseases.
1. A method of stimulating hematopoiesis in a patient in need of such stimulation, wherein said stimulation of hematopoiesis is used to treat myelosuppression arising from chemotherapy or radiotherapy in the patient, said method comprising administering to said patient a pharmacologically effective amount of a composition comprising a purified caprylic salt or caprate salt, wherein said administration is done by a route selected from oral, sublingual, pulmonary, intramuscular, intradermal, subcutaneous and intravenous; and wherein the administration of said compound causes sufficient stimulation of hematopoiesis to treat myelosuppression in the patient.
2. The method of claim 1 wherein said salt is selected from the group consisting of calcium, magnesium, potassium, and sodium salts.
3. The method of claim 2 wherein said salt is calcium caprylate, calcium caprate, sodium caprylate, or sodium caprate.
4. The method of claim 1 wherein stimulating hematopoiesis treats chronic neutropenia in said patient.
5. The method of claim 1 wherein stimulating hematopoiesis treats transient neutropenia in said patient.
6. The method of claim 1 wherein stimulating hematopoiesis treats neutropenia arising from radiotherapy in said patient.
7. The method of claim 1 wherein stimulating hematopoiesis heals a wound in said patient.
8. The method of claim 1 further comprising simultaneous administration of a pharmacologically effective amount of a human colony stimulating factor, wherein the pharmacologically effective amount is reduced in the presence of the caprylic salt or caprate salt.
9. The method of claim 8 wherein the colony stimulating factor is G-CSF or GM-CSF.
10. The method of claim 1 further comprising simultaneous administration of a pharmacologically effective amount of a human cytokine.
11. The method of claim 10 wherein the cytokine is interleukin 2 or interleukin 15.
12. A method of stimulating hematopoiesis in a patient in need of such stimulation, wherein said stimulation of hematopoiesis induces neutrophil mobilization to facilitate bone marrow transplantation in said patient, said method comprising administering to said patient a pharmacologically effective amount of a purified caprylic salt or caprate salt, wherein said administration is done by a route selected from oral, sublingual, pulmonary, intramuscular, intradermal, subcutaneous and intravenous; and wherein the administration of said compound induces sufficient neutrophil mobilization to facilitate bone marrow transplantation in the patient.
13. The method, according to claim 12 , wherein said salt is selected from the group consisting of calcium, magnesium, potassium, and sodium salts.
14. The method, according to claim 12 , wherein said salt is calcium caprylate, calcium caprate, sodium caprylate, or sodium caprate.
15. The method, according to claim 12 , further comprising simultaneous administration of a pharmacologically effective amount of a human colony stimulating factor, wherein the pharmacologically effective amount is reduced in the presence of the caprylic salt or caprate salt.
16. The method, according to claim 12 , wherein the colony stimulating factor is G-CSF or GM-CSF.
17. The method, according to claim 12 , further comprising simultaneous administration of a pharmacologically effective amount of a human cytokine.
18. The method, according to claim 12 , wherein the cytokine is interleukin 2 or interleukin 15.